Fineline Cube

Follow:
14409 Articles
FDA Prasad Outlines New Vaccine Approval Process After Covid-19 Safety Analysis
Others

FDA Prasad Outlines New Vaccine Approval Process After Covid-19 Safety Analysis

China Health: Life Expectancy Hits 79 Years as Hospitals Expand and Expenditure Controlled
HospitalPolicy / Regulatory

China Health: Life Expectancy Hits 79 Years as Hospitals Expand and Expenditure Controlled

CANbridge's maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus
CompanyDrug

CANbridge’s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus

WuXi Biologics CRDMO Qatar MOU Establishes First Middle East Center
CompanyDeals

WuXi Biologics CRDMO Qatar MOU Establishes First Middle East Center

Johnson & Johnson's Nipocalimab Secures EU Approval for Myasthenia Gravis
CompanyDrug

Johnson & Johnson’s Nipocalimab Secures EU Approval for Myasthenia Gravis

Regeneron Tessera Partner on TSRA-196 Gene-Writing Therapy for AATD with $275M Deal
CompanyDeals

Regeneron Tessera Partner on TSRA-196 Gene-Writing Therapy for AATD with $275M Deal

ChemPartner and Fosun Pharma Forge CRO-CDMO Alliance to Accelerate Drug Development
CompanyDeals

ChemPartner and Fosun Pharma Forge CRO-CDMO Alliance to Accelerate Drug Development

Microport's PulseMagic PFA-Catheter Secures NMPA Approval as First Pressure-Monitoring Device in China
CompanyMedical Device

Microport’s PulseMagic PFA-Catheter Secures NMPA Approval as First Pressure-Monitoring Device in China

Humanwell's HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction
CompanyDrug

Humanwell’s HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction

Sanyou Bio and FatiAbGen Forge AI-STAL Alliance for Korea and Global Markets
CompanyDeals

Sanyou Bio and FatiAbGen Forge AI-STAL Alliance for Korea and Global Markets

Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND
CompanyDrug

Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND

Mabwell's 9MW1911 Cuts COPD Exacerbations by 30% in Phase 2a, FDA Accepts US Trial Application
CompanyDrug

Mabwell’s 9MW1911 Cuts COPD Exacerbations by 30% in Phase 2a, FDA Accepts US Trial Application